Compare EVER & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVER | DNA |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.5M | 835.7M |
| IPO Year | 2018 | 2020 |
| Metric | EVER | DNA |
|---|---|---|
| Price | $29.10 | $7.61 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 8 | 3 |
| Target Price | ★ $32.33 | $8.00 |
| AVG Volume (30 Days) | 684.7K | ★ 2.4M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 198.86 | 46.49 |
| EPS | ★ 1.53 | N/A |
| Revenue | $163,349,000.00 | ★ $170,155,000.00 |
| Revenue This Year | $18.77 | N/A |
| Revenue Next Year | $11.02 | $7.59 |
| P/E Ratio | $18.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.88 | $5.37 |
| 52 Week High | $31.20 | $18.22 |
| Indicator | EVER | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 36.89 |
| Support Level | $22.38 | $6.65 |
| Resistance Level | $31.20 | $7.50 |
| Average True Range (ATR) | 1.57 | 1.18 |
| MACD | -0.06 | -0.41 |
| Stochastic Oscillator | 66.18 | 0.65 |
EverQuote Inc operates an online marketplace for insurance shopping, connecting consumers with insurance providers, including carriers and agents. Its marketplace is powered by proprietary data and technology platform that delivers high-intent, pre-validated consumer referrals aligned with insurers underwriting and profitability requirements. The platform provides transparency and campaign management tools, enabling providers to evaluate marketing spend performance and manage return on investment. Consumers can visit insurance provider websites, engage by phone, or submit data to receive quotes. Services are free for consumers, and the company derives revenue principally from consumer inquiries sold as referrals to insurance providers. It derives a majority of revenue from Direct channels.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.